Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Account Payables (2022 - 2025)

Entrada Therapeutics (TRDA) has 4 years of Change in Account Payables data on record, last reported at -$877000.0 in Q4 2025.

  • For Q4 2025, Change in Account Payables fell 130.82% year-over-year to -$877000.0; the TTM value through Dec 2025 reached -$1.8 million, down 281.53%, while the annual FY2025 figure was -$1.8 million, 281.53% down from the prior year.
  • Change in Account Payables reached -$877000.0 in Q4 2025 per TRDA's latest filing, down from $1.3 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $4.6 million in Q4 2022 and bottomed at -$4.4 million in Q2 2023.
  • Average Change in Account Payables over 4 years is $104625.0, with a median of -$317500.0 recorded in 2024.
  • Peak YoY movement for Change in Account Payables: tumbled 384.42% in 2023, then soared 516.88% in 2025.
  • A 4-year view of Change in Account Payables shows it stood at $4.6 million in 2022, then crashed by 47.62% to $2.4 million in 2023, then increased by 18.29% to $2.8 million in 2024, then tumbled by 130.82% to -$877000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Account Payables were -$877000.0 in Q4 2025, $1.3 million in Q3 2025, and -$321000.0 in Q2 2025.